September 18, 2020: BioVid Corporation: Condor Hospitality Announces Termination of Merger Agreement With NHT Operating Partnership 19 September 2020


Condor Hospitality Trust, Inc. (NYSE American: CDOR) (the "Company") today announced that it has terminated its merger agreement with NHT Operating Partnership, LLC, the operating partnership of NexPoint Hospitality Trust (TSVX: NHT), and certain of its affiliates, effective September 18, 2020.

Pursuant to its rights under the merger agreement, the Company terminated the merger agreement due to failure of NHT's operating partnership to consummate the acquisition of the Company and for material breaches of the merger agreement by NHT's operating partnership and its affiliates. Pursuant to the merger agreement, the Company is entitled to receive a termination fee of $11,925,000 within five business days of its termination of the merger agreement. The Company continues to reserve all other rights and remedies.







BioVid Corporation

Key Stats

Estimated Revenue (TTM): $10 Million

Estimated Employees: 51



BioVid Corporation provides primary market research services to pharmaceutical, biotechnology, medical device, and diagnostics companies in the United States and internationally. The company was founded in 1998 and is based in Princeton, New Jersey.


PermID: 5044191825


Industry: Media


September 18: BioVid Corporation: Stirling Square Capital Partners' Fourth Fund Invests in DOCU Nordic in Partnership With TA Associates

Stirling Square Capital Partners ("Stirling Square"), a leading pan-European mid-market private equity firm, today announced an additional investment in portfolio company DOCU Nordic Group Holdings AB ("DOCU Nordic" or the "Company") in partnership with TA Associates, a leading global growth private equity firm. TA Associates will acquire a significant minority stake in the Company from Stirling Square's Third Fund alongside Stirling Square's Fourth Fund, which becomes the majority shareholder in DOCU Nordic.

Headquartered in Ljusdal, Sweden, DOCU Nordic is the leading provider of business intelligence and data analytics services within the construction, real estate and healthcare markets in Scandinavia, Central Europe and Iberia.

During Stirling Square's Third Fund's ownership, DOCU Nordic substantially developed its product offerings and capabilities while expanding its geographic reach. The Company recently announced the acquisition of Vortal in Portugal, which will add strategic e-tendering capabilities and a presence in Iberia. The new investment is the latest step in DOCU Nordic's aim to create the leading construction technology and construction management eco-system in Europe, with significant opportunity for future buy-and-build activity.

Henrik Lif, Partner of Stirling Square, commented, "We believe that DOCU Nordic is an outstanding business that provides business critical and high-value services to a broad customer base. We are delighted to continue our investment journey with the Company in partnership with TA Associates. DOCU Nordic has demonstrated industry leading innovation in the construction, real estate and healthcare sectors. With the recent acquisition of Vortal in Portugal, the Company takes a further step geographically with the leading public e-tendering platform in Southern Europe.

September 18: BioVid Corporation: Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors.

Source: Company Website

September 18: BioVid Corporation: Vifor Pharma Group Announces Successful Sale of OM Pharma

Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include:

A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple

This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days.

OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years.

Source: Company Website

September 17: BioVid Corporation: SK Magic Wins Gold Medal at IDEA 2020 for Triple Care Dishwasher

SK Magic's Triple Care Dishwasher won Gold Medal at IDEA 2020. Triple Care Dishwasher is a third-generation dishwasher model that offers not only dishwashing and drying but also care and storage functions. With a clean and linear design, it was created in a more sophisticated and professional image by reflecting the product concept to also function as storage. Another element that was evaluated highly at the awards was the product's design resembling a luxurious cupboard to provide an interior decoration effect for the kitchen. Triple Care Dishwasher became the world's first dishwasher to be honored with the IDEA Gold Medal, the first prize in the Home/Kitchen Appliances category. (Graphic: Business Wire)

Source: Company Website

September 17: BioVid Corporation: Arkema: Bostik Inaugurates a New Industrial Adhesives Plant in Japan

Arkema (Paris:AKE) announces the start-up of a new world-scale industrial adhesives plant in Japan. Those new capacities will enable Bostik to serve its Japanese customers in the continuously growing markets of diapers, hygiene, packaging, labelling, transportation and electronics. This investment is in line with Bostik's growth and geographical expansion strategy.

Bostik, the Adhesive Solutions segment of Arkema, continues the development of its industrial adhesives business and announces the start-up of a new plant in Nara, Japan, within the Bostik-Nitta JV, 80% owned by the Group.

This new facility includes several production lines dedicated, on the one hand, to adhesives for the non-woven industry (diapers and hygiene) and, on the other hand, to the industrial markets of packaging, labelling, transportation and electronics. It will enable Bostik to support the strong growth of its customers in the disposable hygiene sector in Japan and to expand the manufacturing of certain industrial adhesives ranges in Asia.

Source: Company Website

September 17: BioVid Corporation: COVID-19 Recovery Analysis: Gamification Market | Increasing Adoption Of Gamification In E-learning to boost the Market Growth | Technavio

Technavio has been monitoring the gamification market and it is poised to grow by $ 17.56 bn during 2020-2024, progressing at a CAGR of over 27% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Source: Company Website

September 17: BioVid Corporation: AM Best to Discuss Reinsurance Industry Outlook, COVID-19 Impact, European Insurance Market Segment at Annual Briefing

AM Best will present a market briefing exploring the state of the global reinsurance industry on 22 September 2020, 3:00 p.m.-4:30 p.m. (CEST).

Source: Company Website

September 15: BioVid Corporation: Monocle Acquisition Corp. Files Registration Statement on Form S-4 with Preliminary Proxy Statement/Prospectus in Connection with Proposed Business Combination with AerSale

AerSale Corp. ("AerSale" or the "Company"), a leading integrated global provider of aviation aftermarket products and services, announced today that Monocle Acquisition Corporation (Nasdaq: MNCL), a special purpose acquisition company, has filed an amended preliminary proxy statement/prospectus as part of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission ("SEC"). This filing is in connection with the recently announced revised business combination between AerSale and Monocle. Completion of the transaction, which is expected in early Fourth Quarter of 2020, is subject to approval by Monocle shareholders and other customary closing conditions.

While the registration statement has not yet become effective and the information contained therein is subject to change, it provides important information about Monocle's proposed business combination with AerSale. Once the registration statement has been declared effective by the SEC, the final joint proxy statement/prospectus will be mailed to shareholders of Monocle prior to shareholder vote on the proposed transaction. To view the Form S-4 filing on the SEC website, click here.

Headquartered in Coral Gables, Florida and with strategically located operating facilities, AerSale serves a growing global customer base. The Company's management team, averaging approximately 25 years of directly related multi-disciplined industry experience, has established customer relationships across major airlines, cargo operators, e-commerce and express freight providers, MRO shops, OEMs, government entities, and aircraft leasing companies. Supported by proprietary aircraft, engine and component pricing, utilization and transaction data, unique fleet analytics, and a highly structured opportunity identification and valuation process, AerSale's leadership has demonstrated financial success across economic cycles, and has the Company well-positioned to grow in the aftermarket sector as commercial aviation recovers in 2021 and beyond.

September 15: Events Calendar: BioVid Corporation: PotlatchDeltic Executives to Present at the D.A. Davidson 19th Annual Diversified Industrials & Services Conference

PotlatchDeltic Corporation (NASDAQ: PCH) announced today that Eric J. Cremers, president and chief operating officer, and Jerald W. Richards, vice president and chief financial officer, will provide a company overview to investors at the D.A. Davidson 19th Annual Diversified Industrials & Services Conference, September 22, 2020 at approximately 5:30 pm Eastern Time.

Source: Company Website

September 14: BioVid Corporation: NICE Honors CX Excellence Award Winners at Interactions Live, Celebrating the Delivery of Exceptional Experiences and CX Agility Through Innovation

NICE (Nasdaq: NICE) today announced the winners of its CX Excellence Awards 2020. Winning organizations were honored for leveraging innovation to drive exceptional customer and employee experiences and improve the bottom line. The 16 award winners across five categories will be recognized at Interactions Live, NICE's first-ever virtual conference highlighting the path to uncompromising customer service via best practices for agility, flexibility and adaptability in today's changing reality. The winners were also featured in a commemorative digital magazine which highlights how they used innovation to provide brand-differentiating customer service.

Source: Company Website

September 14: BioVid Corporation: GoodRx Announces Launch of Initial Public Offering

a leading consumer-focused digital healthcare platform in the United States, today announced the launch of its initial public offering of 34,615,384 shares of its Class A common stock. The offering consists of 23,422,727 shares of Class A common stock offered by GoodRx and 11,192,657 shares of Class A common stock to be sold by certain of GoodRx's existing stockholders. GoodRx will not receive any proceeds from the sale of the shares by the selling shareholders. The underwriters will have a 30-day option to buy an additional 5,192,307 shares of Class A common stock from GoodRx at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is currently expected to be between $24 and $28 per share. GoodRx intends to list its Class A common stock on the NASDAQ Global Select Market, under the ticker symbol "GDRX."

Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Barclays will act as lead bookrunners for the proposed offering. BofA Securities, Citigroup, Credit Suisse Securities (USA) LLC, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, and Evercore ISI will act as additional bookrunners, and Citizens Capital Markets, KKR Capital Markets, LionTree Advisors, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus & Co., LLC and Ramirez & Co., Inc. will act as co-managers for the proposed offering.

Source: Company Website

September 14: BioVid Corporation: ORIX to Acquire One of the Largest U.S. LIHTC Fund Portfolios through Agreement with Boston Capital

ORIX Corporation ("ORIX") announced today that Boston Financial Investment Management ("Boston Financial"), a wholly-owned subsidiary of ORIX Corporation USA ("OCU"), has entered into an agreement with Boston Capital ("Boston Capital") to acquire Boston Capital's low-income housing tax credit ("LIHTC") fund portfolio. The closing of the transaction is subject to customary closing conditions and approvals.

Source: Company Website

September 14: BioVid Corporation: Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations

Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations

Source: Company Website

September 10: BioVid Corporation: 'Fake News' Meets Real Adversary as $1M Leaders Prize Awarded to Canadian AI Solution

Communitech, in conjunction with The Leaders Fund, Schulich Foundation and University of Waterloo, is pleased to announce that Bill (Yu) Wu, of the team Ava, has been selected as the winner of the $1-million Leaders Prize. For this first-of-its-kind competition, Bill developed and submitted a solution that used artificial intelligence (AI) to solve a global problem that has been undermining democracies across the globe: 'fake news' and the spread of misinformation.

Source: Company Website

September 10: BioVid Corporation: AM Best Assigns Indicative Issue Credit Rating to Pacific LifeCorps Senior Unsecured Notes

AM Best has assigned an indicative Long-Term Issue Credit Rating of "a" to the forthcoming new senior unsecured notes to be issued by Pacific LifeCorp (Wilmington, DE). The outlook assigned to this Credit Rating (rating) is stable. The existing ratings of Pacific LifeCorp and its subsidiaries are unchanged.

Pacific LifeCorp intends to use the proceeds for general corporate purposes, and to strengthen financial flexibility. AM Best notes that proforma financial leverage and interest coverage metrics are expected to remain at appropriate levels.

This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper media use of Best's Credit Ratings and AM Best press releases, please view Guide for Media - Proper Use of Best's Credit Ratings and AM Best Rating Action Press Releases.

Source: Company Website

September 10: BioVid Corporation: Tortoise Acquisition Corp. II Announces Pricing of Upsized $300,000,000 Initial Public Offering

Tortoise Acquisition Corp. II (the "Company") today announced the pricing of its initial public offering ("IPO") of 30,000,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (the "NYSE") and trade under the ticker symbol "SNPR.U" beginning September 11, 2020. Each unit consists of one of the Company's Class A ordinary shares and one-fourth of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company's Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols "SNPR" and "SNPR WS," respectively.

Barclays and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. AmeriVet Securities, Inc. is acting as co-manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 4,500,000 units at the initial public offering price to cover over-allotments, if any.

The offering is expected to close on September 15, 2020, subject to customary closing conditions.

The public offering is being made only by means of a prospectus. When available, copies of the prospectus related to the offering may be obtained from Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, email:, tel: (888) 603-5847; and Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, email:, tel: (866) 471-2526.

A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission (the "SEC") on September 10, 2020.

September 09: Events Calendar: BioVid Corporation: Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference

-Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that Tom Civik, Chief Executive Officer of Five Prime Therapeutics, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therapeutics, will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference on Thursday, September 10th at 9:00am Pacific Time / 12:00pm Eastern Time.

The fireside chat will be webcast and may be accessed from the "Events & Presentations" section of the Company's website at: Five Prime will maintain an archived replay of the webcast on its website for approximately 30 days after the conference.

Source: Company Website

September 09: BioVid Corporation: Genesis Ray Launches Unique GIS-Powered Renewable Energy Analytics Tool to Meet Rising Demand for Upfront Intelligence on Clean Energy Opportunities in Asia

Genesis Ray Energy ("Genesis Ray"), the Singapore- based clean energy research company providing innovative data analytics products on renewable energy and energy infrastructure mapping services, has launched the GenRay EXPLORER(TradeMark), an intuitive online analytics tool that enables developers, investors and OEMs. to screen, compare and evaluate gas and power assets in South and South East Asia.

Source: Company Website

September 09: BioVid Corporation: JCPenney Reaches Agreement in Principle with Brookfield Property Group and Simon Property Group to Acquire Retail and Operating Assets

-J.C. Penney Company, Inc. (OTCMKTS: JCPNQ) today announced that it has reached an agreement in principle to sell JCPenney through a court-supervised sale process. The Company plans to seek approval of a disclosure statement and, ultimately, confirmation of a plan of reorganization in parallel with the sale process. Related to the sale process, JCPenney expects to execute a "stalking horse" asset purchase agreement ("APA"), which will track an executed letter of intent, outlining the following:

Source: Company Website

September 07: BioVid Corporation: Brazil : Total Resigns From its Role of Operator in the Foz Do Amazonas Basin

Regulatory News:

Total (Paris:FP) (LSE:TTA) (NYSE:TOT) announces that it has notified its partners on August 19 about its resignation from its role of operator for five exploration blocks, located in the Foz do Amazonas Basin, 120 kilometers offshore Brazil. These exploration blocks are referenced as FZA-M-57, FZA-M-86, FZA-M-88, FZA-M-125 and FZA-M-127.

Total has informed the National Agency of Petroleum, Natural Gas and Biofuels (ANP) of this decision, that opens a period of 6-months during which a new operator will be appointed and to whom the operated activities will be handed over. During this period, Total has the duty to continue monitoring all regulatory processes on behalf of its part

Source: Company Website

September 07: BioVid Corporation: Veolia Announces the Launch of a Shareholding Plan Reserved for Approximately 140,000 Employees of the Group

Veolia Environnement (Paris:VIE) announces the launch of a new shareholding plan for the Group's employees. This plan is offered to approximately 140,000 employees of the Group, aiming at associating them with the development and performance of Veolia. The settlement and delivery of the new shares shall take place on December 17, 2020.

Source: Company Website


Andrew Aprill, President

Andrew has spent his career delivering strategic brand insights to clients in the healthcare arena by combining deep therapeutic knowledge with innovative research methods. His expertise is in applying cutting-edge methodologies in a bottom-lined oriented, client-focused context. He has provided guidance to pharmaceutical clients with products at all stages in the lifecycle, but tends to concentrate on compounds in the pre-launch and early launch phases. Over the past decade, BioVid has become one of the most sought-after market research firms in the industry. This is due, in part, by Andrew's unbending belief that the role of market research is best characterized as a tool for decision support rather than as a decision making tool. That is, marketing research should never take the place of sound business judgment or be used by a manager for decision avoidance.

In addition to his role at BioVid, Andrew has been a guest lecturer on strategic marketing at The Wharton Business School, Neibrija International School of Business, Universidad Nebrija, Spain, and Guangzhou University, People's Republic of China.

PermID: 5044191825

Created by for News Bites Finance